Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASH
Claret Capital Partners is providing growth funding of €43m as part of Inventiva's €130m debt financing
Latest in a series of late stage, European biotech investments by Claret Capital as part of its expansion in life sciences
London, 16 June, 2026, Claret Capital Partners (‘Claret'), Europe's largest independent growth debt fund manager has made an investment through its funds, of €43m in Inventiva (Euronext Paris and NASDAQ:IVA), a clinical-stage biopharmaceutical company developing an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), a common and progressive chronic liver disease.
Headquartered in Dijon, France, Inventiva is advancing lanifibranor, an oral once-daily pan-PPAR agonist designed to simultaneously activate all three subtypes of "peroxisome proliferator-activated receptors," or PPARs, targeting metabolic, inflammatory and fibrotic pathways. The therapy is currently being evaluated in the Phase 3 NATiV3 trial with anticipated top-line Phase 3 readout in Q4 2026.
The financing is provided alongside funds and accounts managed by BlackRock and totals up to €130 million in committed tranches, with an additional uncommitted tranche of up to €20 million. It is part of Inventiva's comprehensive capital structure optimization, including debt and equity financing, announced by Inventiva on June 2, 2026.
MASH is a progressive liver disease in which fat build-up triggers chronic inflammation and scarring. Currently affecting millions of people globally, without treatment, it can advance to cirrhosis or liver failure and is projected to become the leading cause of liver transplants for women in the US*. It affects an estimated 20–25% of patients already diagnosed with fatty liver disease globally, representing a largely underserved population.
Daniel Mallon, Principal at Claret Capital Partners commented: "It is great to be able to support Inventiva at a pivotal stage in its clinical journey. The Company has demonstrated encouraging clinical progress through its Phase 2b results and we look forward to the outcome of its Phase 3 trial anticipated later this year. This financing provides additional flexibility as Inventiva moves towards anticipated key clinical and regulatory milestones in 2026 and 2027."
Joey Mason, Life Sciences Venture Partner at Claret Capital Partners said: "This investment demonstrates the type ...
